Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma. Kaseb A, Pawlik TM. Lancet 2025 Oct 19:S0140-6736(25)02104-X. doi: 10.1016/S0140-6736(25)02104.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kaseb A, Pawlik TM. Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma. Lancet 2025 Oct 19:S0140-6736(25)02104-X. doi: 10.1016/S0140-6736(25)02104.
PMID: 41125108